RecruitingPhase 2NCT06969573

Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

The Impact of Inhaled Treprostinil on Dyspnea and Exercise Intolerance in Mild COPD; a Pilot and Feasibility Trial


Sponsor

University of Alberta

Enrollment

20 participants

Start Date

Jun 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic) The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity


Eligibility

Min Age: 50 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether inhaled treprostinil — a drug currently used for a different lung condition — can relieve breathlessness and improve exercise tolerance in people with mild chronic obstructive pulmonary disease (COPD). **You may be eligible if...** - You have been diagnosed with mild COPD based on lung function tests (FEV1/FVC ratio below 0.70 and FEV1 of at least 80% predicted) - You experience shortness of breath or reduced ability to exercise - You have not been able to find adequate relief from standard COPD treatments **You may NOT be eligible if...** - You already have heart failure or pulmonary arterial hypertension - You have a known low platelet count (thrombocytopenia) - Your resting blood pressure is very low (below 90/50 mmHg) - You have a known sensitivity or allergy to prostanoid-type drugs - You have severe liver disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer

COMBINATION_PRODUCTTreprostinil Inhalation Solution 36 mcg

Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

COMBINATION_PRODUCTTreprostinil Inhalation Solution 78 mcg

Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer


Locations(1)

Clinical Physiology Laboratory

Edmonton, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06969573


Related Trials